Maintenance Therapy With Toripalimab and Capecitabine Versus Capecitabine Alone in High-risk Nasopharyngeal Carcinoma

N3 classification, rENE positivity is a high-risk type of locally advanced nasopharyngeal carcinoma. EBV DNA remaining at detectable levels after induction chemotherapy is also a characteristic of high-risk nasopharyngeal carcinoma. Based on the available evidence, patients with high-risk nasopharyngeal carcinoma are recommended to receive oral maintenance therapy to reduce the risk of failure. The purpose of this study was to conduct a prospective, multicenter, randomized phase III clinical trial to determine whether maintenance therapy with triprilimab combined with capecitabine is better t

Trial Details

NCT ID
NCT06277050
Phase
PHASE3
Sponsor
Jiangxi Provincial Cancer Hospital
Status
RECRUITING
Cancer Type
Nasopharyngeal Head and Neck Cancer
Interventions
  • Maintenance Therapy with Toripalimab and Capecitabine
  • Maintenance Therapy with Capecitabine
Locations (sample)
  • Ganzhou, Jiangxi, China|25.84664,114.9326
  • Guangzhou, Jiangxi, China|27.38164,114.13426
  • Nanchang, None Selected, China|28.68396,115.85306

Key Eligibility Criteria

  • Pathologically confirmed nasopharyngeal carcinoma;
  • High-risk nasopharyngeal cancer meets one of three points: a. TanyN3M0; b. High-grade rENE, coalescent nodal or invasion of surrounding structures …
  • 18-70 years old, both genders; 4. ECOG≤1; 5. Received 2-3 cycles of induction chemotherapy and concurrent chemoradiotherapy (intensity-modulated ra…
  • 7\. All women with fertility potential must undergo a urine or serum pregnancy test during screening and the results are negative; 8. Written infor…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Nasopharyngeal Head and Neck Cancer Trials on Trialify →